Biologics for Chronic Rhinosinusitis With Nasal Polyps: The Who, When, Why, and Which One – Allergy Track
English
Recorded Courses
hosted by Integrity Continuing Education Inc.
hosted by Integrity Continuing Education Inc.
attend it anywhere online
category
Medicine, Nursing
Allergy & Immunology, Nurse Practitioners
price
Free
Release date: 29-07- 2022,Expiration date: 29- 07- 2023,Program Overview:,Until recently, the only treatment choices for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery, though endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their patients with CRSwNP who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy, criteria that should be used when choosing between biologics and surgery, and patient education in regards to treatment with biologics. This program will increase understanding of new and emerging therapies, how they fit in with existing treatments, and best practices for the management of patients with CRSwNP.,Learning Objectives:,Upon completion of this educational activity, participants should be able to:,• Incorporate a patient-centric focus into evaluating the physical, extranasal, and psychosocial aspects of disease burden for each patient with CRSwNP,• Differentiate between each new and emerging biologic treatment for CRSwNP using data from clinical trials and other analyses,• Elucidate best practices criteria for recommending sinus surgery or biologic therapy and when systemic corticosteroids may or may not be appropriate.,Additional details will be posted as soon as information is available.